Community/Retail

Jeffrey Gudin, MD, outlines the steps pharmacists should take to reduce opioid-induced constipation.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses the latest advancements in OIC treatment.

Meijer has announced that it is unveiling a Heritage Center rich with company history from its founder Hendrik Meijer's first arrival in the United States through the retailer's most recent innovations and expansions.

The U.S. Department of Health and Human Services, in collaboration with Walgreens, will help provide more than $10 million worth of free flu shot vouchers this flu season to improve flu immunization rates among uninsured Americans.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses potential adverse effects associated with naloxone.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacy-based OIC care differs from other settings.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system pharmacists can assess patients' risk for opioid overdose.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses OTC recommendations for OIC symptoms.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how often pharmacists work with OIC patients.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system and community pharmacists can work together to provide naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses prices of naloxone products.

Jeffrey Gudin, MD, describes the impact of opioid-induced constipation on patients taking opioids.

The FDA has approved Novartis's etanercept-szzs (Erelzi), a biosimilar to Amgen's etanercept (Enbrel), for the treatment of several inflammatory diseases.

Today, Janet Woodcock, MD, Director, Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) delivered a keynote address at Leading on Biosimilars: The 2016 GPhA Biosimilars Council Conference.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses where fiber supplementation fits into OIC care.

CVS Health has announced the rollout of Project Health, its annual free health services campaign, at select CVS Pharmacy locations in 10 multicultural communities across the country.

There are many misconceptions surrounding pain management, especially when it comes to opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, describes how clinicians can determine whether an opioid has abuse-deterrent properties.

J. David Haddox, DDS, MD, describes the pharmacist's role in deterring opioid abuse.

The answer may surprise you.

J. David Haddox, DDS, MD, describes the most common method of opioid abuse.

J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, explains how most nonmedical opioid users obtain the drug.

Does the prospect of continuing lower reimbursement rates, crazy hours, longer phone wait times, and slow and inefficient pharmacy software have you considering a new career?

Erin L. Albert, MBA, PharmD, JD, is the interviewee, with the tables turned with special guest podcast host Lauren Steinbach.

Pharmacists are much more likely to see prescriptions for sodium-glucose co-transporter 2 (SGLT2) inhibitors than obesity medications, recent prescription data reveal.

Sagent Pharmaceuticals is recalling one lot of injectable oxacillin because a single vial contained dark particulate matter identified as iron oxide.